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Abstract
Background: Fas receptor-mediated eosinophil apoptosis is currently forwarded as a mechanism resolving
asthma-like inflammation. This view is based on observations in vitro and in airway lumen with unknown
translatability to airway tissues in vivo. In fact, apoptotic eosinophils have not been detected in human diseased
airway tissues whereas cytolytic eosinophils abound and constitute a major mode of degranulation of these cells.
Also, Fas receptor stimulation may bypass the apoptotic pathway and directly evoke cytolysis of non-apoptotic
cells. We thus hypothesized that effects of anti-Fas mAb in vivo may include both apoptosis and cytolysis of
eosinophils and, hence, that established eosinophilic inflammation may not resolve by this treatment.
Methods: Weeklong daily allergen challenges of sensitized mice were followed by airway administration of anti-
Fas mAb. BAL was performed and airway-pulmonary tissues were examined using light and electron microscopy.
Lung tissue analysis for CC-chemokines, apoptosis, mucus production and plasma exudation (fibrinogen) were
performed.
Results: Anti-Fas mAb evoked apoptosis of 28% and cytolysis of 4% of eosinophils present in allergen-challenged
airway tissues. Furthermore, a majority of the apoptotic eosinophils remained unengulfed and eventually exhibited
secondary necrosis. A striking histopathology far beyond the allergic inflammation developed and included
degranulated eosinophils, neutrophilia, epithelial derangement, plasma exudation, mucus-plasma plugs, and
inducement of 6 CC-chemokines. In animals without eosinophilia anti-Fas evoked no inflammatory response.
Conclusion:  An efficient inducer of eosinophil apoptosis in airway tissues in vivo, anti-Fas mAb evoked
unprecedented asthma-like inflammation in mouse allergic airways. This outcome may partly reflect the ability of
anti-Fas to evoke direct cytolysis of non-apoptotic eosinophils in airway tissues. Additionally, since most apoptotic
tissue eosinophils progressed into the pro-inflammatory cellular fate of secondary necrosis this may also explain
the aggravated inflammation. Our data indicate that Fas receptor mediated eosinophil apoptosis in airway tissues
in vivo may cause severe disease exacerbation due to direct cytolysis and secondary necrosis of eosinophils.
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Background
Apoptosis of inflammatory cells followed by their swift
removal through phagocytosis is considered a major
mechanism of resolution of inflammatory conditions
[1,2]. The most common chronic inflammatory disease,
asthma is characterized by eosinophilia, epithelial
derangement, plasma exudation, and hypersecretion
[3,4]. The role of the eosinophil in this disease is currently
under intense investigation [5] and much interest has
been devoted to apoptosis of eosinophil granulocytes
[6,7]. In the absence of growth factors or in the presence
of glucocorticoids, eosinophils in vitro exhibit massive
apoptosis and, eventually, secondary necrosis [8-10]
occurs. A specific mode of inducing death through apop-
tosis is stimulation of Fas antigen (Fas), a cell surface pro-
tein expressed in most cells including eosinophil
granulocytes [11]. Fas may also trigger an alternative
death pathway leading to cytolysis of cells without prior
apoptosis [12]. Eosinophil cytolysis causing extra-cellular
spilling of eosinophil granules commonly occurs in asth-
matic bronchi [13] but it is not known whether stimula-
tion of the Fas-receptor may evoke cytolysis of
eosinophils.
Apoptosis of eosinophil granulocytes is effectively
induced in vitro by cross-linking of Fas membrane recep-
tors with agonistic anti-Fas monoclonal antibody (mAb)
[11,14,15]. Similarly, administration of anti-Fas mAb
intra-nasally to the lungs of allergic mice has been shown
to induce apoptosis of eosinophils in the airway lumen
[7]. This latter finding is of interest because apoptotic eosi-
nophils have also been observed in asthmatic sputa fol-
lowing disease exacerbation [16]. As a corollary it has
been suggested that agents inducing eosinophil apoptosis
may be developed as novel anti-asthma drugs [17-19].
However, the occurrence of apoptotic cells in the airway
lumen cannot tell about the presence of such cells in the
airway tissues [20]. Indeed, apoptotic eosinophils have so
far rarely have been seen in airway tissues [20] where eosi-
nophils instead may be silently eliminated from the tissue
through alternative clearance mechanisms such as egres-
sion into the airway lumen followed by mucociliary clear-
ance [21,22]. Even at resolution of established airway
eosinophilia, spontaneously or by effects of anti-inflam-
matory steroids, apoptotic eosinophils have not been
detected in lung tissues [21]. The absence of apoptotic
eosinophils in human diseased tissues together with the
common occurrence of cytolytic eosinophils suggest that
these cells are more prone to undergo cytolysis than apop-
tosis in inflamed airways (35). Also, since inducement of
apoptosis in tissue eosinophils has not yet been compel-
lingly demonstrated it remains speculative what actually
may result in vivo when apoptosis of these cells occurs.
Differing from the prior reports, that focused on airway
lumen data [7,23], this study explores airway tissue effects
of anti-Fas mAb given to mouse allergic airways with
already established eosinophilic inflammation. Impor-
tantly, we have included a detailed transmission electron
microscopy analysis to assess cell phenotypes such as
apoptotic and cytolytic cells that are basically defined by
ultrastructural characteristics [24]. Here we demonstrate
that anti-Fas mAb evoked apoptosis of more than 1/4th of
the airway tissue eosinophils and that a majority of these
cells proceeded to undergo secondary necrosis. Direct
cytolysis of non-apoptotic tissue eosinophils was also
induced by the present anti-Fas mAb treatment. Further-
more, at variance with previous interpretations of findings
in the airway lumen and in vitro [7,17,23] we now demon-
strate that the established allergic inflammation of airway-
lung tissues was not resolved. On the contrary, as indi-
cated by a wide range of indices, the allergic eosinophilic
inflammation was greatly aggravated producing for the
first time in mouse models several hallmarks of human
asthma. This in vivo study thus demonstrates an unprece-
dented asthma-like histopathology in mouse airways and,
unravels significant risks involved in drug-induced stimu-
lation of death-receptors.
Methods
Animals
8–10 weeks old male C57BL/6 mice (Bomholtgard, Den-
mark) were used. Mice were kept in well-controlled ani-
mal housing facilities and fed ad libitum. The study was
approved by the Regional Ethics Committee in Malmoe-
Lund, Sweden.
Allergen sensitization and challenge protocol
The ovalbumin sensitization and challenge protocol was
similar to that described previously [25,26]. Briefly, all
mice were immunized to chicken OVA (Grade III; Sigma,
St Louis, MO) via i.p injection with 10 µg OVA, adsorbed
to 1 mg of alum. Fourteen days after the immunization
mice were exposed daily for seven days to aerosolized
OVA at a concentration of 1 % wt / vol for 30 minutes.
Control animals received saline challenge (Figure 1).
Study design
After the lung tissue eosinophilia was established (day
22), 30 µg of anti-Fas mAb (purified hamster Anti-mouse
Fas antibody, clone Jo2; Pharmingen, Palo Alto, CA) or a
matched isotype control antibody (hamster IgG, control)
was administered to the lungs via the intranasal route as
previously described [7]. The dose of anti-Fas mAb was
chosen according to a dose-response study carried out by
Tsuyuki et al where 30 µg was markedly effective at induc-
ing apoptosis of airway luminal eosinophils [7]. Unless
otherwise stated each experimental group consisted of 8
animals. Outcome measurements were made at 8 and 24Respiratory Research 2005, 6:90 http://respiratory-research.com/content/6/1/90
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h after each treatment (OVA/OVA+ IgG and OVA/OVA +
anti-Fas mAb) (Figure 1). One group of animals with
established eosinophilia treated with anti-Fas mAb was
followed for 72 h after intra-nasal treatment (n = 3).
Importantly, effects of anti-Fas mAb were also examined
in mice lacking eosinophilic airway inflammation. Thus
mice immunized with OVA and subjected to saline chal-
lenges were given anti-Fas mAb (or the isotype control
IgG) and airway histopathology examined after 24 h. All
animals were sacrificed by ip injection of pentobarbital
immediately followed by bronchoalveolar lavage (BAL)
and dissection of the lungs and tracheobronchial airways.
Bronchoalveolar lavage (BAL) and quantification of 
luminal cells
BAL was performed via a ligated tracheal cannula. One ml
of PBS was allowed to passively enter the lungs at a pres-
sure of 10 cm H20. This procedure was carried out twice.
The obtained BAL-fluid (BALF) from each animal was
immediately centrifuged (700 g, 5 min) and the superna-
tant frozen for ELISA analysis. The cell pellet was washed
and resuspended in 250 µl PBS containing 10% FCS. The
total number of cells was quantified using a hemocytom-
eter and 5 × 105 cells cytocentrifuged to microscope slides.
Differential cell counts were performed on May-Grünwald
Giemsa stained slides and percentage of eosinophils, lym-
phocytes, neutrophils, and macrophages determined by
counting 200 cells in a blinded manner. To obtain the
absolute number of each leukocyte subtype in each BALF,
the percentage of cells was multiplied by the total number
of cells recovered from the BAL.
Lung tissue processing for histology analysis
From each animal 4 tissue samples were taken from the
superior lung lobes at the level just below the root of the
lung. One tissue sample was immersed in Stefanini's fixa-
tive (2% paraformaldehyde and 0.2% picric acid in 0.1 M
phosphate buffer pH 7.2) overnight, rinsed repeatedly in
Tyrode buffer supplemented with 10% sucrose, and
finally frozen in TissueTEK (Miles, Inc., Elkhart, IN). The
frozen specimens were stored at -80°C until used for his-
tochemistry. A separate sample was immersed overnight
in buffered 4% paraformaldehyde (pH 7.2) and thereafter
dehydrated and embedded in paraffin. An additional
sample was placed in a fixative consisting of a mixture of
3% formaldehyde and 1% glutaraldehyde in 0.1 M phos-
phate buffer, pH 7.2 and used for transmission electron
microscopic (TEM) analysis. The rest of the lung tissue
was immediately frozen for mRNA analysis.
Staining and counting lung tissue eosinophils
Eosinophils were detected by histochemical visualization
of cyanide-resistant eosinophil peroxidase (EPO) activity
[27]. In brief, 5 µm cryosections were incubated for 8 min
at room temperature in PBS buffer (pH 7.4) supple-
mented with 3.3-diaminobenzidine tetrahydrochloride
Study design Figure 1
Study design. All animals were immunized with OVA and 14 days later exposed to aerosol challenge with OVA for 7 days to 
establish tissue and lumen eosinophilia. Treatment with anti-Fas mAb or isotype control IgG was administered intra-nasally at 
day 22 and outcome measurements including BAL and tissue sampling were made at 8 and 24 h after treatment.
Daily Allergen Challenges 
Termination, 8 h and 24 h  
after treatment 
Day 15  20  22  0 14 16  17  18  19 21 
Immunization OVA/alum ip 
23
Treatment with Anti-Fas mAb 
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(60 mg / 100 ml; SIGMA), 30% H202 (0.3 ml / 100 ml),
and NaCN (120 mg / 100 ml). Slides were then rinsed in
tap water and mounted in Kaisers medium (Merck, Darm-
stadt, Germany). Eosinophils were identified by their dark
brown reaction product and quantified as number of per-
ibronchial eosinophils / 0.1 mm2 tissue area.
Staining of mucus-containing cells, mucus secretions, and 
mucus-plasma plugs
5 µm sections of paraffin embedded lung tissue were cut,
dewaxed to water and then stained with periodic acid-
Schiff reagent (PAS) as previously described [26]. Epithe-
lial integrity was examined and specific signs of injury-
repair processes [28] were looked for. A mucus plug index
was established as number of large and medium airways
with tethered secretions/plugs divided by the total
number of airways in each tissue section and multiplied
by 100 to obtain percentage values. The presence of
mucus plugs was also confirmed by transmission electron
microscopy. Immunostaining for fibrinogen was per-
formed using a polyclonal Ab (rabbit anti-fibrinogen
1:320, Dako, Copenhagen Denmark) and visualized
using a secondary FITC antibody (swine anti-rabbit 1:80,
Dako, Copenhagen, Denmark.).
Detection of apoptosis, secondary necrosis and eosinophil 
cytolysis
Apoptotic cells in the lung tissue were mainly detected
using TUNEL-technique. A combined staining with
TUNEL and Chromotrope-2R identified apoptotic eosi-
nophils as previously described [10]. Importantly, to
assess an apoptotic morphology, detect engulfed eosi-
nophils, and different activation grades of eosinophils,
ultrastructural analysis using transmission electron micro-
scopy was also performed as previously described [10].
Ultrathin sections (60–80 nm) for electron microscopy
were cut on an LKB MK III ultratome and contrasted with
uranyl acetate and lead citrate. The sections were exam-
ined using a Philips CM-10 transmission electron micro-
scope and the ultrastructural criteria for eosinophil
apoptosis were eosinophils displaying cell shrinkage,
intact cell membrane and nuclear chromatin condensa-
tion as previously described [10]. Secondary necrosis was
defined as cells exhibiting typical features of apoptosis e.g.
nuclear condensation, but with clear signs of membrane
rupture and extra cellular distribution of cell debris. Mac-
rophages were identified using TEM and their content of
eosinophil granules or whole eosinophil cell material was
also quantified using TEM. Eosinophil cytolysis, which
emerges as a major mode of eosinophil degranulation in
asthma and rhinitis is characterized by chromatolysis of
the cell nucleus and rupture of the cell membrane,
whereby the protein-rich specific eosinophil granules are
released into the tissue [29].
Measurement of mRNA expression
Total RNA from the lungs was extracted with RNAzol B
(Tel-Test, Inc., Friendswood, TX) according to the manu-
facturer's protocol. Chemokine mRNA expression was
determined by multiprobe RNAse protection assay (RPA)
using the Riboquant RPA kit (mCK-5, Pharmingen, San
Diego, CA), according to the supplier instructions and as
previously described [30]. The identity and quantity of
each mRNA species in the original RNA sample were then
determined based on the signal intensities given by the
appropriately sized, protected probe fragment bands. 1 µg
RNA was loaded for each sample and the differences in
sample loading were normalized by a factor of the ratio of
the housekeeping genes L32 and GAPDH.
Data Analysis
Histology analyses were performed and quantified in a
blinded manner. Tissue sections from eight animals were
investigated in each treatment and control group. An
Olympus BX60 microscope, equipped with an Olympus
DP50 digital camera was used for imaging. Wilcoxon
Rangsumtest for statistical analysis was performed using
Analyze It™ (Analyse-it software, Ltd. Leeds, UK). Data are
expressed as mean ± SEM. A value of p < 0.05 was consid-
ered statistically significant.
Results
Fas-induced apoptosis and reduced number of eosinophils 
in the airway lumen
The present weeklong, daily allergen challenges with OVA
(see study design, Figure 1) established a marked airway
tissue and lumen eosinophilia. Post-challenge intra-nasal
administration of anti-Fas mAb to the lungs of these mice
decreased the number of eosinophils in the airway lumen
(BALF) at 8 and 24 hours (Figure 2A) compared to ani-
mals receiving isotype control Ab. Microscopic analyses of
cytospin slides showed that a majority of the lumen eosi-
nophils in anti-Fas treated animals had an apoptotic mor-
phology. Other luminal cells including neutrophils,
lymphocytes and monocytes/macrophages remained via-
ble after the anti-Fas treatment. These lumen data agree
with previously reported observations [7].
Fas-induced apoptosis of lung tissue eosinophils and 
insufficient clearance of apoptotic eosinophils
The airway tissue eosinophilia was not reduced by anti-
Fas mAb treatment (Figure 2B, and 2C). Yet, contrasting
the lack of apoptotic eosinophils in the airway tissues of
animals receiving allergen challenge or allergen challenge
plus isotype control Ab (Figure 3A, and 3C; Figure 4A;
Table 1), apoptotic eosinophils occurred frequently in
anti-Fas treated lung tissues especially in granulomas
around bronchi and bronchioles (Figure 3B, and 3D; Fig-
ure 4B, and 4C; Table 1). Apoptosis is defined by
ultrastructural criteria [24]. In this study apoptoticRespiratory Research 2005, 6:90 http://respiratory-research.com/content/6/1/90
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After eosinophilia had been established in the immunized mice anti-Fas mAb or isotype control Ab was administered locally to  the lungs followed by BAL and tissue sampling at 8 and 24 hours Figure 2
After eosinophilia had been established in the immunized mice anti-Fas mAb or isotype control Ab was administered locally to 
the lungs followed by BAL and tissue sampling at 8 and 24 hours. The number of eosinophils in airway lumen (A) and airway tis-
sue (B) was quantified as described in detail in the methods section. White bars represent mice given control Ab and black bars 
mice given anti-Fas mAb. Error bars indicate the standard error of the mean for each group of mice (n = 8, ** = p < 0.01). Per-
ibronchial eosinophilia induced by the OVA challenges is shown in (C).
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eosinophils were thus assessed not only by staining tech-
niques but foremost by transmission electron microscopy
(TEM) analysis demonstrating transformation of the bi-
lobular nuclei of normal eosinophils into a condensed
dark nucleus and by cell shrinkage occurring without rup-
ture of the cell membrane (Figures 4 and 5). The inability
of anti-Fas mAb treatment to resolve the tissue eosi-
nophilia was associated with poor clearance of the tissue
eosinophils. As suggested by the reduced lumen eosi-
nophilia (Figure 2A), clearance through egression of cells
into the lumen was reduced. There was further an insuffi-
cient clearance of apoptotic tissue eosinophils through
engulfment (Figure 4B). Indeed, many apoptotic tissue
eosinophils underwent secondary necrosis (see below).
Fas-induced secondary necrosis of apoptotic tissue 
eosinophils
Apoptotic eosinophils in the late stages of apoptosis, not
being engulfed, proceeded to undergo secondary necrosis.
Already at 8 h following treatment with anti-Fas almost
Representative light micrographs of mouse lung tissue using Htx-staining in control (A) and anti-Fas mAb treated animals (B) at  24 h Figure 3
Representative light micrographs of mouse lung tissue using Htx-staining in control (A) and anti-Fas mAb treated animals (B) at 
24 h. Htx-staining shows dark condensed (pycnotic) nuclei of eosinophils and disturbed epithelial lining. Very few TUNEL-pos-
itive apoptotic cells were present in control treated animals (C) whereas a large number of TUNEL-stained cells was detected 
in anti-Fas mAb treated animals (D), almost all of which were shown to be apoptotic eosinophils by double chromotrope 2R 
and TUNEL staining (see also Figure 4).Respiratory Research 2005, 6:90 http://respiratory-research.com/content/6/1/90
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half of the apoptotic eosinophils and at 24 h a majority of
them exhibited secondary necrosis (Table 1). Typical signs
of the secondary necrosis were a condensed dark nucleus
and cell membrane rupture (Figures 4C and 5C) as previ-
ously described [10]. These cells further exhibited piece-
meal degranulation of the specific granules (Figure 5C).
Transmission electron micrographs of lung tissue from mice with OVA-induced eosinophilia Figure 4
Transmission electron micrographs of lung tissue from mice with OVA-induced eosinophilia. Control mice treated with the 
isotype control Ab showed no sign of eosinophil apoptosis at 8 h (A) and 24 h (not shown). In mice treated with anti-Fas mAb 
there were numerous apoptotic eosinophils in the lung tissues at both 8 and 24 hours after treatment (B and C, respectively). 
The apoptotic eosinophils were rarely engulfed although macrophages (labeled M) commonly occurred in the tissue (B). By 24 
h a majority of the apoptotic eosinophils exhibited signs of secondary necrosis and severe inflammation was recorded including 
neutrophil infiltration (arrow) and derangement of the epithelial lining (labeled E).Respiratory Research 2005, 6:90 http://respiratory-research.com/content/6/1/90
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These micrographs illustrate characteristic eosinophil phenotypes present in mouse airways in this study Figure 5
These micrographs illustrate characteristic eosinophil phenotypes present in mouse airways in this study: (A) viable non-
degranulating eosinophil, the only phenotype found in lung tissues of allergen challenged animals; (B) apoptotic eosinophil 
exhibiting nuclear condensation, cell shrinkage, and an intact cell membrane; (C) an apoptotic eosinophil exhibiting secondary 
necrosis involving cell membrane rupture and piecemeal degranulation; (D) a cytolytic eosinophil exhibiting chromatolysis, cell 
membrane rupture, and spilling of electron-dense specific granules into the tissue (arrow).Respiratory Research 2005, 6:90 http://respiratory-research.com/content/6/1/90
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Primary cytolysis of non-apoptotic tissue eosinophils
After treatment with anti-Fas mAb 2–4 % of the tissue
eosinophils exhibited primary cytolysis more so at 8 h
than at 24 h (Table 1). As described previously for eosi-
nophils in human diseased airway tissues [13,20,29]
these cells were without signs of apoptosis, exhibited little
piecemeal degranulation and were characterized by chro-
matolysis and cell membrane rupture including the spill-
ing of electron dense (protein-rich) specific granules into
the tissue (Figure 5D, Table 1).
Anti-Fas mAb caused up-regulation of CC-chemokines
Treatment with anti-Fas mAb resulted in a marked up-reg-
ulation of a range of CC-chemokines involved in recruit-
ment of eosinophils and neutrophils. Thus, mRNA levels
for MIP-1α, eotaxin, and MIP-1β were up-regulated (Fig-
ure 6A, and 6B). Two chemokines, IP10 and MCP-1, that
are involved in severe inflammatory processes [31], were
not expressed in isotype IgG treated animals, but were
induced by anti-Fas mAb treatment (Figure 6A, and 6B).
Additional signs of Fas-induced aggravation of airway 
inflammation
The airway epithelium was grossly changed after anti-Fas
mAb treatment exhibiting injury with an abnormally
loose structure (Figure 3A, and 3B) and containing many
mucus producing cells protruding into the airway lumen.
Furthermore, the mucus was being expelled into the air-
way lumen resulting in tethered secretions and mucus-
plugs (Figure 7A–D). Immunostaining for fibrinogen
showed that the mucus-plugs contained fibrinogen (Fig-
ure 7E), a marker of plasma exudation [4]. Another sign of
pro-inflammatory anti-Fas mAb-induced events was a
marked influx of neutrophils (Figure 4C; Table 1). The
general inflammatory picture including secondary necro-
sis of apoptotic eosinophils remained 72 h after anti-Fas
mAb treatment (data not shown). None of the above
inflammatory indices was observed in animals treated
with isotype control.
Administration of anti-Fas mAb to animals without 
eosinophilic inflammation
To investigate whether anti-Fas treatment produced
inflammation in lungs where eosinophils were absent we
used four groups of animals immunized with OVA and
challenged with saline. In these animals, that did not
develop eosinophilic inflammation and goblet cell meta-
plasia, neither anti-Fas mAb treatment nor isotype control
treatment induced apoptosis (at 8 h and 24 h). Impor-
tantly, neutrophilia or other pro-inflammatory signs were
not detected in the saline-challenged and anti-Fas treated
lung tissues.
Discussion
This study demonstrated that anti-Fas mAb induced eosi-
nophil apoptosis in both airway lumen and tissue. How-
ever, this treatment did not resolve the established allergic
eosinophilic inflammation. Instead, of being engulfed a
majority of the apoptotic tissue eosinophils underwent
secondary necrosis. Additionally, the Fas receptor stimula-
tion evoked direct cytolysis of non-apoptotic tissue eosi-
nophils. As a result we could demonstrate that an efficient
inducer of eosinophil apoptosis in vivo, anti-Fas mAb
produced unprecedented asthma-like inflammation
involving degranulation of eosinophils, increased expres-
sion of CC-chemokines, epithelial derangement, plasma
exudation, neutrophilia, tethered hypersecretion, and
occurrence of significant mucus-plasma plugs in mouse
allergic airways. Yet, anti-Fas treatment of mice without
airway eosinophilia did not evoke any sign of inflamma-
tion. The present data on airway tissue events in vivo con-
tradict the current notion, based on interpretations of
findings in vitro and in the airway lumen, that inducement
of eosinophil apoptosis is a therapeutic modality in
asthma.
Current allergic mouse models of asthma are character-
ized by eosinophilia and by airway remodeling including
transformation of the epithelium into a secretory (PAS-
Table 1: Viable, apoptotic, necrotic and cytolytic eosinophils in mice with OVA-induced established lung tissue eosinophilia.
Viable eosinophils A Apoptotic eosinophilsA Cytolytic eosinphilsA NeutrophilsB
Intact Necrotic
OVA/control 8 h 100 0 0 0 3 ± 1
OVA/FAS 8 h 69 ± 7 19 ± 5 8 ± 3 4 ± 1 12 ± 4
OVA/control 24 h 100 0 0 0 5 ± 0.5
OVA/FAS 24 h 70 ± 4 13 ± 3 15 ± 2 2 ± 0.7 24 ± 2
A = Eosinophil phenotypes are presented as % of total number of eosinophils in each transmission electron microscopy grid (n = 8).
B = Number of neutrophils occurring in each grid (n = 8).Respiratory Research 2005, 6:90 http://respiratory-research.com/content/6/1/90
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CC-chemokine mRNA expression 8 h (A) and 24 h (B) after treatment with anti-Fas mAb or isotype control (IgG) Figure 6
CC-chemokine mRNA expression 8 h (A) and 24 h (B) after treatment with anti-Fas mAb or isotype control (IgG). Two days 
post allergen challenge expression of 5 different CC-chemokines in the lung was up-regulated compared to immunized control 
animals receiving saline challenges. Treatment with anti-Fas mAb post allergen challenge further increased the expression of 
eotaxin MIP-1α, and MIP -1β, and additionally induced the expression of IP-10 and MCP-1. Data are mean ± SEM. **p < 0.01 
indicates differences between OVA and saline treatments. §§ p < 0.01 indicates difference between anti-Fas mAb treated and 
control-treated OVA-challenged animals.
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Observations in allergen challenged animals demonstrating anti-Fas-induced mucus-exudate plugs (A,C,D,E) compared to con- trol isotype antibody (IgG) treatment (A,B) Figure 7
Observations in allergen challenged animals demonstrating anti-Fas-induced mucus-exudate plugs (A,C,D,E) compared to con-
trol isotype antibody (IgG) treatment (A,B). The occurrence of mucus-exudate plugs is expressed as percentage affected air-
ways in each tissue section in control mice (white bars) and in mice treated with anti-Fas mAb (black bars) at 8 and 24 hours 
(A). Bars indicate the standard error of the mean for each group of animals (n = 8, ** = p < 0.01). Histochemical staining with 
periodic acid-Schiff reagent (PAS) illustrated mucus-containing cells (B,C) and so did the transmission electron micrograph (D). 
Tethered secretions and lumen plugs occurred foremost in anti-Fas treated airways (C,D;E). Fibrinogen immuno-reactivity was 
distributed in the mucus plugs exclusively in anti-Fas treated airways (E).
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positive) cell lining [32]. Otherwise the signs of
inflammation are mild or absent, and the mouse models
of asthma may be criticized for their lack of disease-like
pathophysiology and histopathology [33]. It is, therefore,
of interest that the present mouse lungs could exhibit
'asthma-like' exudative, eosinophilic, epithelial, and neu-
trophilic inflammation. After the combined allergen chal-
lenge and anti-Fas treatment the present tissue
eosinophils further showed several signs of activation
ranging from cytolysis of non-apoptotic eosinophils to
secondary necrosis of apoptotic eosinophils. Cytolysis has
not previously been observed in mouse airway tissue eosi-
nophils [34], but is of particular interest because this
mode of degranulation is prominent in human airway
eosinophilic diseases [29,35]. Although the mechanisms
involved in the present primary cytolysis of eosinophils
are not known it is possible that Fas receptor stimulation
directly induced cytolysis in these eosinophils through
subcellular effects critically deviating from the apoptosis
pathway [12]. The time course of cytolysis in this study
with more cytolysis occurring at 8 h than at 24 h (contrary
to secondary necrosis) supports the possibility that Fas
directly evoked this mechanism. Fas administration in
this study also evoked tethered luminal secretions and
mucus plugs, as observed in asthma [36], considerably
more so than observed after allergen challenge alone (this
study). Moreover, as indicated by fibrinogen immunore-
activity, the present anti-Fas treatment evoked a plasma
exudation process that has not previously been demon-
strated in the allergic mouse models of asthma. In allergic
asthma luminal levels of a large protein such as fibrinogen
may better than albumin reflect the plasma exudation
process, a hallmark of the disease especially at exacerba-
tions [4]. Prior work has already established that anti-Fas
antibody may evoke inflammatory responses such as hep-
atitis and pneumonitis [37]. Indeed, the pro-inflamma-
tory aspect of Fas has already prompted repeated studies
on the effect of this agent in the airways of allergic mice
[23]. However, all previous workers, focusing largely on
lumen findings, have arrived at the consensus notion that
Fas-induced effects in mouse allergic airways are of an
anti-inflammatory nature. The present study demon-
strates the opposite. Our findings further indicate that
careful studies are warranted to assess risks associated
with treatment with adenovirus expressing Fas ligand. The
latter construct was recently promoted as an anti-asthma
treatment option [19].
Few non-eosinophilic cells became apoptotic in this
study. We also detected no inflammatory response in anti-
Fas-treated mice that had not developed lung eosinophilia
indicating that eosinophlis were essentially involved in
the present Fas-induced aggravation of allergic inflamma-
tion. Further studies are warranted to explain the present
finding that both airway tissue and lumen eosinophils are
particularly sensitive to Fas-receptor stimulation. The
present observation that macrophages (or other cells) are
not immediately engulfing the apoptotic eosinophils tal-
lies with observations suggesting that pulmonary macro-
phages may be less efficient than commonly studied
peritoneal macrophages as regards engulfment of apop-
totic cells [38]. Reflecting an insufficient clearance, necro-
sis of tissue-dwelling, apoptotic eosinophils was a
prominent feature in this study. Secondary necrosis of
apoptotic cells is a pro-inflammatory event [39] and so is
likely the primary cytolysis of eosinophils [35]. Both
modes of cell death could thus be causally involved in the
present aggravation of the allergic inflammation. In view
of the dependence of Fas-induced inflammation on estab-
lished lung eosinophilia the necrosis and the cytolysis
phenomena may be major pathogenic mechanisms in this
study. Also, as suggested by the present observations 3
days after anti-Fas treatment the induced inflammatory
process is self-sustained continuing for a considerable
length of time even in the absence of further airway
provocations.
If cell clearance through apoptosis and engulfment are not
working well in the lung other modes for non-inflamma-
tory resolution of lung eosinophilia are needed. In fact, it
was recently proposed that transepithelial cell egression
may efficiently, and without affecting the integrity of the
epithelial lining, resolve an established airway tissue eosi-
nophilia [22]. Egression into the airway lumen clearly
occurred in this study as evidenced by a developing BAL
fluid eosinophilia in allergen challenged animals. The
occurrence of eosinophil apoptosis in the present Fas-
exposed airway tissue must have reduced the egression
simply because dying cells cannot migrate. Inferentially,
failure of tissue eosinophils to egress into the airway
lumen (due to their apoptotic condition) explains in part
the present maintained tissue eosinophilia. A reduced
egression would also explain in part the demonstration in
this and previous studies [7] of anti-Fas mAb-induced
diminution of lumen eosinophilia in allergic airway
inflammation. The possibility of such complex relation-
ships between cell numbers and phenotypes of airway
lumen and tissue, respectively, underscores the difficulty
in drawing conclusions merely based on airway lumen
data. Similarly, it is puzzling that mouse eosinophils
exhibit piecemeal dagranulation in the airway lumen [40]
but not in the airway tissue [41,42].
The present anti-Fas-induced inflammation was probably
associated with de novo recruitment of eosinophils
because the expression of several eosinophil-recruiting
chemokines [43], including eotaxin, and MIP-1α were
markedly up-regulated. The present non-specific increase
in CC-chemokines may in part be due to an unrestricted
release of bioactive proteins from eosinophils undergoingRespiratory Research 2005, 6:90 http://respiratory-research.com/content/6/1/90
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cytolysis or secondary necrosis in airway tissues. Besides
eosinophilia increased airway neutrophilia is common
especially in severe asthma [44]. The increased presence of
neutrophils is therefore an interesting feature of the
present anti-Fas treated airways. Fas itself may act as a che-
moattractant for neutrophils [45] but neutrophilia was
not detected in the present control group challenged with
saline and receiving anti-Fas treatment. It has been sug-
gested that tissue-toxic agents from neutrophils as well as
eosinophils have a causative role in epithelial
derangement. Epithelial cell loss alone may also evoke
significant local neutrophilia in vivo [28]. These aspects
indicate that neutrophilia is an expected component in
the present airways where degranulated eosinophils and
epithelial derangement were prominent features.
Conclusion
This study demonstrates for the first time that eosinophil
apoptosis can be induced to a great extent in airway tis-
sues in vivo. But then, in contrast to current notions, this
response was not associated with resolution of the estab-
lished eosinophilic inflammation. This finding alone
questions the proposed role of apoptosis for efficient,
non-inflammatory clearance of a major granulocyte in
allergic airways. Yet, we additionally discovered here that
the combined effect of allergic eosinophilic inflammation
and anti-Fas evoked not only apoptosis but also second-
ary necrosis as well as primary cytolysis of the tissue-
dwelling eosinophils. These latter effects were associated
with multifaceted inflammatory processes developing far
beyond the allergic inflammation in this species and
involving significant components of hallmark features of
asthma. Hence, Fas-receptor stimulation of airway tissue
eosinophils in vivo emerges as a significant pathogenetic
mechanism and unravels significant risks involved in
drug-induced stimulation of death-receptors.
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